Multicenter Phase II/III Clinical Study of Lipoplatin plus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer.

Trial Profile

Multicenter Phase II/III Clinical Study of Lipoplatin plus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Cisplatin; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 07 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top